Dear Team, Today, we’re hitting an exciting milestone in our journey—welcoming our tenth team member! This moment marks not just growth in numbers but a significant step in our evolution as a company. Reflecting on our journey, I’m so proud of how far we’ve come. We...

We were featured in The Globe and Mail article titled “In the quest for new medicines, developers seek to make AI their divining rod”.

Molecular Forecaster Inc. (MFI) is excited to announce a new partnership with NMX Research and Solutions Inc. (NMX) that will expand the service offerings of both companies.

We have a few words that sum up the last year or two at MFI: evolution is a good one. We’re an early-stage business, with big projects, great partners and customers, and lofty goals. We’re also a values-driven company, focused on our corporate and social...

In the ever-evolving world of machine learning in drug discovery, benchmarking datasets play a pivotal role in driving progress and innovation. They serve as a critical tool for evaluating and comparing different algorithms and models. However, as the field advances…

Our docking software, Fitted, was used to perform covalent docking to the Transient Receptor Potential Ankyrin 1 to help understand the binding mode of organic polysulfides.

As a McGill University spinout company, we at Molecular Forecaster are thrilled to support the recent landmark government investment into our alma mater through “DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R)”…

This morning, our CSO, Nicolas Moitessier, was invited to give a presentation at the 90th Acfas Congress about developing computational methods to help discover molecules targeting RNA.

On April 19, our CEO Josh Pottel and our CSO and co-founder Nicolas Moitessier both presented in the webinar on Artificial Intelligence in Life Sciences organized by BIOQuebec and GENAIZ.

On May 1st, our CEO Josh Pottel will share his experience as an entrepreneur at the symposium organized by the Chemical Institute of Canada at Concordia University.

Earlier this week, we were featured in the last edition of Genetic Engineering and Biotechnology News in an article about artificial intelligence for drug design.

We have published our recent research on the SARS-Cov2 NSP13 helicase, target of the second CACHE challenge organized by the Structural Genomics Consortium (SGC).

We express our gratitude to the adMare BioInnovations teams following our graduation from their Pilot Accelerator Program created in 2020 and highlight our achievements thanks to the program.

Our CSO, Pr. Nicolas Moitessier is the 2023 winner of the Biological and Medicinal Chemistry Lectureship Award which he will receive in June at the Canadian Chemistry Conference and Exhibition in Vancouver.

Our docking software, Fitted, was used to perform covalent docking to enzymes in a recently published work on Frontiers of Chemistry by a team of Queen’s University of Belfast Pharmacy School.

Our Scientist II Mihai Burai-Patrascu will be receiving the CNC/IUPAC Travel Award and present a part of his work at the IUPAC | CHAINS Congress this summer in the Netherlands.

Our metabolism prediction software, Impacts, has been featured by Macs in Chemistry. The site is intended to provide a resource for chemists using Apple Macintosh computers and reviews the latest trends in drug discovery.

We are delighted to introduce two new members of our team: Dr. Suneel Kumar BVS – Director of CADD, and Matej Janezic, PhD – Associate Scientist II.

Our Ph.D. student intern, Vrinda Nair, gave an interview to Le Devoir newspaper to talk about her work on the use of artificial intelligence in the study of hybrid antibiotics.

Recent drug discovery research from our CSO’s lab at McGill University showcases hit discovery, covalent design, selectivity consideration, and more using our software.

Our CEO, Josh Pottel attended the Gold Leaf Awards and BIONATION 2022 hosted by BIOTECanada in Ottawa and shared his thoughts.

We participated in the first CACHE challenge organized by the Structural Genomics Consortium (SGC). After submitting our results to SGC we published our group’s effort.

Molecular Forecaster Inc. (MFI) is exited to announce a partnership with adMare BioInnovations (adMare) to deliver computer-aided drug design (CADD) resources to selected R&D programs in adMare’s pipeline.